Previous studies have explored the role of JAK2 (V617F) allelic burden as a potential differentiator between individual MPN subtypes (Park et al., 2013); highest levels were found in PV and the lowest in ET patients. Here, JAK2 is linked to myeloproliferative neoplasm.